The present invention relates to compounds that inhibit VIPR2 in the CNS, pharmaceutical compositions comprising said compounds, and methods of using such compounds and compositions in the treatment of a CNS disorder such as a behavioral disorder, including but not limited to schizophrenia.La présente invention concerne des composés inhibant le VIPR2 dans le SNC, des compositions pharmaceutiques comprenant lesdits composés, et des méthodes dutilisation de tels composés et de telles compositions dans le traitement dun trouble du SNC tel quun trouble du comportement, notamment mais non exclusivement la schizophrénie.